Xilio Therapeutics, Inc.’s Post

Taconic Field Application Scientist Dr. Ditte Olsen discusses the far-reaching consequences of murine Fc gamma receptors in preclinical drug studies. Discover how super immunodeficient FcResolv® NOG mice are offering researchers greater confidence and more translatable data while utilizing fewer resources in this webinar: https://bit.ly/3SCtS6y

🚀 "Launching ASPET Discovery is a critical step in providing more options for researchers as we navigate the open access transition," shares David Jackson, CAE, MBA of American Society for Pharmacology and Experimental Therapeutics - ASPET. Discover how this new journal aligns with the future of scientific publishing and supports ASPET’s mission. 🔗 Read more in our latest A100 article: https://loom.ly/8rreeUk 🔗 And take a deeper dive on our our blog here: https://loom.ly/W9zcYq0 #A100 #OpenAccess

💡 Join HitGen Inc.'s upcoming webinar to discover how DNA-encoded libraries are revolutionizing early-stage, small-molecule drug discovery, especially for targeting G protein-coupled receptors (#GPCRs). 🧬 Learn about the remarkable advancements and impact of #DNAEncodedLibrary in identifying hit compounds for #DrugDevelopment. The expert speakers, Alex Shaginian, PhD, MBA, Rusty Montgomery and David Israel will cover the unique advantages of DNA-encoded libraries for various targets and provide an overview of different platforms and their applications in drug discovery. BioAge Labs will also share insights from their study on novel indazole #NLRP3 inhibitors, demonstrating the selection strategy and analysis of small molecule structures and activities. ➡️ REGISTER HERE: https://buff.ly/3WeHJCo #SmallMolecule #DrugDevelopment #DrugDiscovery #DrugManufacturing #SmallMoleculeDrug

💡 Join HitGen Inc.'s upcoming webinar to discover how DNA-encoded libraries are revolutionizing early-stage, small-molecule drug discovery, especially for targeting G protein-coupled receptors (#GPCRs). 🧬 Learn about the remarkable advancements and impact of #DNAEncodedLibrary in identifying hit compounds for #DrugDevelopment. The expert speakers, Alex Shaginian, PhD, MBA, Rusty Montgomery, and David Israel will cover the unique advantages of DNA-encoded libraries for various targets and provide an overview of different platforms and their applications in drug discovery. BioAge Labs will also share insights from their study on novel indazole #NLRP3 inhibitors, demonstrating the selection strategy and analysis of small molecule structures and activities. ➡️ REGISTER HERE: https://buff.ly/3WeHJCo #SmallMolecule #DrugDevelopment #DrugDiscovery #DrugManufacturing #SmallMoleculeDrug

Looking forward to the 6th RSC BMCS / DMDG New Perspectives in DMPK conference today. In particular the 2 talks from AZ scientists on clinical and preclinical #PROTAC & #protein_degrader PK. #DMPK24 #Medicinal_Chemistry

Endocannabinoid system as a therapeutic target for psychostimulants relapse: A systematic review of preclinical studies https://lnkd.in/eAH8KzDW

Traditional preclinical efficacy assessments often rely on broad behavioral measures, making it hard to distinguish different mechanisms of action and accurately predict clinical outcomes or side effects. This highlights the need for more sensitive, predictive evaluations. ➡️If you are at the #ECNP2024, check out poster #P1600, presented by 𝗝𝗼𝗻𝗮𝘁𝗵𝗮𝗻 𝗭𝗮𝗽𝗮𝘁𝗮, to learn about Inscopix's circuit-based neurobehavioral assay for 𝗽𝗿𝗼𝗳𝗶𝗹𝗶𝗻𝗴 𝗽𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝗻𝘁𝗶𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗮𝗻𝘁𝘀.

🌟 Meet our new community member: Ary Marsee from HepX Predict! 🌱 Last week, we kicked off our Science and Life Science Validation program. Stay tuned as we introduce our incredible lineup over the coming weeks! HepX Predict is revolutionizing drug development with patented 3D liver organoid technology. By bridging the gap between pre-clinical studies and clinical success, they're tackling the challenge of drug failures head-on. With 70-80% of drugs failing in human trials due to ineffective preclinical models, and liver toxicity contributing to over 20% of these failures, the need for accurate in vitro models is more crucial than ever. Here's to a future of safer and more effective drugs! 💊✨ #DrugDevelopment #Innovation #LifeScience

🌱 🌱 Check out this #HighlyCitedPaper# by Peter Hamar et al: "Recent Preclinical and Clinical Progress in Liposomal Doxorubicin" You can find it at: https://lnkd.in/gnRUNmWp

[POSTER] 📃 "Advancing Drug Discovery through 3D Cell Models: Unveiling Novel Hits and Mechanisms" 👨🔬 N. Ancellin, O. Duchamp, K. Herry, N.Legrand, C.Parsy (Oncodesign Services) This poster discusses the limitations of traditional 2D cell cultures in replicating in vivo complexity and emphasizes the benefits of using 3D cell models in drug development. Read it now here 👉 https://ow.ly/QcqP50QAcol #3Dcells #InVitro #PDXO #OncodesignServices